FirstHealth of the Carolinas

Clinical Trial Details

Study Title: RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Study Type: Interventional
Study Condition: Prostate Cancer
Investigator: Dr. Stephen King
Phone: (910) 715-1056
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Men, ages 18 and older, diagnosed with adenocarcinoma of the prostate currently treated primarily with radical prostatectomy. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Radiation Therapy Oncology Group
Study Rationale: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen deprivation therapy is more effective for prostate cancer.
Study Purpose: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
Study Link:
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.